Annual Report for FY 2020/21 has been published
On January 17 BRAIN Biotech AG has published its Annual Report including the detailed consolidated financial statements for the fiscal year 2020/21.
As far as the Group’s financial position and operating performance is concerned, the Management Board assessed the overall picture as positive. CEO Adriaan Moelker summarized: “We completed the 2020/21 financial year in September 2021 satisfactorily and in line with our earnings and revenue forecast. Thanks to stringent cost control, we improved our EBITDA as planned, despite continuing our high level of investment in our incubator pipeline and infrastructure. These investments build the pillars for our future growth.”
Looking to the future, CFO Lukas Linnig expressed optimism: “In fiscal year 2020/21 we have added two projects with significant economic value to our incubator pipeline. The BRAIN-Engineered-Cas project, which is based on a proprietary CRISPR-Cas9-independent nuclease, has made significant progress and already started to become a driver for new business generation in the BioScience segment. In addition, the active pharma compound PHA121 to treat the orphan disease HAE promises significant milestone payments and royalties.”
The Management Board provides detailed information on these and other pipeline projects and developments in an interview, which can be found in the company section of the Annual Report.